Table 5 Total frequencies of conventional synthetic and biological DMARDs in the REAL cohort
From: Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study
DMARD | N (%) |
|---|---|
Methotrexate | 748 (66.5) |
Leflunomide | 381 (33.9) |
Hydroxychloroquine | 120 (10.7) |
Sulfasalazine | 55 (4.9) |
Abatacept | 73 (6.5) |
Etanercept | 66 (5.9) |
Tocilizumab | 60 (5.3) |
Adalimumab | 54 (4.8) |
Infliximab | 50 (4.4) |
Rituximab | 49 (4.4) |
Golimumab | 37 (3.3) |
Certolizumab | 17 (1.5) |